Résumé
Purpose: To assess anterior scleral canal opening (ASCO) offset relative to Bruch's membrane opening (BMO) (ASCO/BMO offset) so as to determine neural canal direction, obliqueness, and minimum cross-sectional area (NCMCA) in 362 healthy eyes. Design: Cross-sectional study. Methods: After optical coherence tomography optic nerve head and retinal nerve fiber layer thickness (RNFLT) imaging, BMO and ASCO were manually segmented. Planes, centroids, size, and shape were calculated. Neural canal direction was defined by projecting the neural canal axis vector (connecting BMO and ASCO centroids) onto the BMO plane. Neural canal obliqueness was defined by the angle between the neural canal axis and the BMO plane perpendicular vector. NCMCA was defined by projecting BMO and ASCO points onto a neural canal axis perpendicular plane and measuring the area of overlap. The angular distance between superior and inferior peak RNFLT was measured, and correlations between RFNLT, BMO, ASCO, ASCO/BMO offset, and NCMCA were assessed. Results: Mean (SD) NCMCA was significantly smaller than either the BMO or ASCO area (1.33 (0.42), 1.82 (0.38), 2.22 (0.43) mm2, respectively), and most closely correlated to RNFLT (P <.001, R2 = 0.158). Neural canal direction was most commonly superior-nasal (55%). Mean neural canal obliqueness was 39.4° (17.3°). The angular distance between superior and inferior peak RNFLT correlated to neural canal direction (P ≤.008, R2 = 0.093). Conclusions: ASCO/BMO offset underlies neural canal direction, obliqueness, and NCMCA. RNFLT is more strongly correlated to NCMCA than to BMO or ASCO, and its peripapillary distribution is influenced by neural canal direction.
Langue d'origine | English |
---|---|
Pages (de-à) | 185-205 |
Nombre de pages | 21 |
Journal | American Journal of Ophthalmology |
Volume | 208 |
DOI | |
Statut de publication | Published - déc. 2019 |
Note bibliographique
Funding Information:All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest and the following were reported. S.H.: None; H.Y.: None; S.K.G.: Nonfinancial support—Heidelberg Engineering; H.L.: None; C.H.: None; G.S.: None; J.C.: None; S.D.: Financial support—Legacy Good Samaritan Foundation, Carl Zeiss Meditec, Heidelberg Engineering, NIH/NEI R01-EY-019674; C.A.G.: Financial support—Heidelberg Engineering; J.M.L.: Financial support—Carl Zeiss Meditec, Topcon, Alcon Laboratories, Allergan, Diopsys Corporation, Glaukos Corporation, Heidelberg Engineering, Merz Pharmaceutical,Inc, Optovue,Inc, Quark Pharmaceuticals,Inc, SOLX,Inc; C.Y.M.: Financial support—Heidelberg Engineering; H.A.Q.: Financial support—Heidelberg Engineering; A.F.S.: Financial support—Heidelberg Engineering; B.F.: Financial support—Legacy Good Samaritan Foundation, Inotek Pharmaceuticals; B.C.C.: Financial support—Heidelberg Engineering; C.F.B.: Financial support—NIH/NEI R01-EY021281, Legacy Good Samaritan Foundation, Heidelberg Engineering. Funding/Support: NIH/NEI R01-EY021281; Legacy Good Samaritan Foundation; Heidelberg Engineering, GmbH, Heidelberg, Germany. All authors attest that they meet the current ICMJE requirements to qualify as authors.
Publisher Copyright:
© 2019 The Author(s)
ASJC Scopus Subject Areas
- Ophthalmology